Drug Profile
DS 1093
Alternative Names: DS-1093; DS-1093aLatest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Class Anti-inflammatories; Antianaemics
- Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Inflammatory bowel diseases
Highest Development Phases
- No development reported Inflammatory bowel diseases
- Discontinued Anaemia
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in Japan (PO)
- 28 Jan 2023 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in Japan (Rectal)
- 19 Dec 2018 Chemical structure information added